Management of Asymptomatic Chronic Lymphocytic Leukemia (CLL)

Current Management of Asymptomatic CLL

The watch-and-wait approach continues to be the standard of care in early-stage asymptomatic CLL, as there are no preventative medications proven to improve overall survival when started before symptoms develop, according to the National Comprehensive Cancer Network 1, 2
A recent phase III clinical trial comparing ibrutinib with placebo in asymptomatic patients with Binet stage A and unfavorable-risk CLL confirmed the lack of an overall survival benefit when starting treatment early, despite demonstrating longer time to next treatment, as recommended by the European Society for Medical Oncology 1
For patients with early disease (Binet stage A and B without active disease; Rai 0, I and II without active disease), the standard approach is careful observation with blood cell counts and clinical examinations every 3-12 months, as suggested by the American Society of Clinical Oncology 3, 4, 5
Multiple studies have shown that early treatment with medications does not translate into a survival advantage in patients with early-stage CLL, according to the American Society of Hematology 4, 6

Treatment should only be initiated when patients develop significant B symptoms (fever, night sweats, weight loss), as recommended by the National Comprehensive Cancer Network 3, 7
Cytopenias not caused by autoimmune phenomena are also an indication for treatment, according to the European Society for Medical Oncology 8
Symptoms or complications from lymphadenopathy, splenomegaly or hepatomegaly should prompt treatment initiation, as suggested by the American Society of Clinical Oncology 3
A lymphocyte doubling time of <6 months (only in patients with >30,000 lymphocytes/μL) is another indication for treatment, according to the National Comprehensive Cancer Network 7

Prognostic factors such as IGHV mutation status, del(17p), TP53 mutation, and complex karyotype can help predict time to progression but should not be used as indications for treatment in asymptomatic patients, as recommended by the American Society of Hematology 3, 9
Absolute lymphocyte count alone is not an indication for treatment, according to the National Comprehensive Cancer Network 9
Patients with del(17p) or TP53 mutations have poorer outcomes but still should not receive treatment until they develop symptoms or meet other criteria for active disease, as suggested by the European Society for Medical Oncology 8, 7

Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, or zanubrutinib are treatment options when disease becomes symptomatic, as recommended by the American Society of Clinical Oncology 1
B-cell lymphoma 2 inhibitor (BCL2i) venetoclax combined with obinutuzumab is another treatment option, according to the National Comprehensive Cancer Network 2
For patients with del(17p) or TP53 mutations, BTK inhibitors are preferred as first-line therapy, as suggested by the European Society for Medical Oncology 8, 7

Regular monitoring with blood cell counts every 3-12 months is recommended, according to the American Society of Clinical Oncology 6, 5
Physical examination including careful palpation of lymph nodes, liver, and spleen should be performed regularly, as suggested by the National Comprehensive Cancer Network 6
Attention to development of symptoms that would indicate need for treatment is crucial, according to the American Society of Hematology 3, 9